Trump nominated White House domestic policy aide and physician Heidi Overton in August 2026 to lead the FDA following Marty Makary’s May resignation, with Kyle Diamantas serving as acting commissioner. Overton appeared before the Senate HELP Committee on September 24, where she addressed vaccine safety, mifepristone policy, and efforts to accelerate drug development while emphasizing adherence to existing law. Confirmation faces procedural and political hurdles, including the committee’s narrow Republican majority, questions from Sen. Bill Cassidy on childhood vaccine schedules, and Sen. Josh Hawley’s concerns over abortion-related drug reviews. These factors, alongside the congressional calendar and intra-party divisions, shape current trader assessments of confirmation prospects ahead of a full Senate vote.